3 citations
,
February 2023 in “BMJ Case Reports” OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.
June 2023 in “Lithuanian University of Health Sciences” May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
January 2007 in “UNIFESP Institutional Repository (Universidade Federal de São Paulo)” Addressing anxiety and mood disorders is crucial to reduce medication overuse in chronic migraine patients.
December 2025 in “Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)” Botulinum toxin may reduce inflammation markers in head and neck conditions, but evidence is uncertain.